Parameter
| Biomarker | Neutrophil-lymphocyte ratio (NLR) | Full name | Neutrophil-lymphocyte ratio | Molecular Type | Blood cell ratio (derived metric) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Assessment of immune-inflammatory balance | ||
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Whole blood (blood routine analyzer, neutrophil/lymphocyte count) | ||
| Pathobiological Mechanisms | 1. In inflammatory state, neutrophils increase (bone marrow hematopoietic activation) and lymphocytes decrease (immune depletion), which jointly lead to the increase of NLR; (2) Reflecting the imbalance of intestinal mucosal immune cells, when NLR > 3.0, the mucosal healing rate of UC patients decreased by 40%, and the risk of non-response to anti-TNF in CD patients increased by 2.3-fold; (3) Associated with intestinal barrier disruption, increased NLR was accompanied by decreased expression of tight junction proteins (occludin and claudin-1) | ||||
| Clinical Availability Status | Clinical routine application | ||||
| Notes and Dynamics | (1) Platelet-lymphocyte ratio (PLR) could improve the predictive accuracy of IBD treatment response from 65% to 79%; 2. The 2025 Meta-analysis showed that NLR > 4.5 was an independent risk factor for postoperative recurrence (Rutgeerts score ≥i2) in CD patients (HR=2.8). | ||||